MARKET

KOD

KOD

Kodiak Sciences Inc.
NASDAQ
41.95
-1.16
-2.69%
After Hours: 42.64 +0.69 +1.64% 19:55 04/13 EDT
OPEN
43.35
PREV CLOSE
43.11
HIGH
46.67
LOW
41.60
VOLUME
1.02M
TURNOVER
--
52 WEEK HIGH
46.67
52 WEEK LOW
2.100
MARKET CAP
2.59B
P/E (TTM)
-9.7062
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KOD last week (0406-0410)?
Weekly Report · 19h ago
Weekly Report: what happened at KOD last week (0330-0403)?
Weekly Report · 04/06 10:10
J.P. Morgan Reaffirms Their Buy Rating on Kodiak Sciences (KOD)
TipRanks · 04/04 12:21
Kodiak Sciences CFO John A. Borgeson disposes of common shares worth 1.2 million
Reuters · 04/03 00:27
Kodiak Sciences falls -8.7%
TipRanks · 04/02 16:07
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Reuters · 04/02 07:21
KODIAK SCIENCES INC <KOD.O>: JP MORGAN RAISES TARGET PRICE TO $60 FROM $32
Reuters · 04/02 03:03
Morning News Wrap-Up 4/1/26: Today’s Biggest Stock Market Stories!
TipRanks · 04/01 16:49
More
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Webull offers Kodiak Sciences Inc stock information, including NASDAQ: KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KOD stock methods without spending real money on the virtual paper trading platform.